SCHEMBL3096368

SCHEMBL3096368

C[C@@H](NC(=O)Cc1ccc2cn[nH]c2c1)c1ccc(OCC(F)(F)F)cn1

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CACNA1I Q9P0X4 4/20 0.67
CACNA1G O43497 2/20 0.67
CACNA1H O95180 2/20 0.67
CNR2 P34972 1/20 0.67
KCNH2 Q12809 1/20 0.67
ACACB O00763 1/20 0.43
NTRK1 P04629 1/20 0.39
KMT2A Q03164 3/20 0.38
MEN1 O00255 2/20 0.38
IDH1 O75874 2/20 0.38
CYP17A1 P05093 2/20 0.37
SLC22A12 Q96S37 1/20 0.37
PDE2A O00408 2/20 0.36
POLB P06746 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
SUCNR1 Q9BXA5 1/20 0.36
ROCK2 O75116 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3097144 0.87 CACNA1I (0.67) CACNA1ICACNA1GCACNA1HCNR2KCNH2
SCHEMBL3095548 0.82 CACNA1I (0.65) CACNA1ICACNA1GCACNA1HCNR2KCNH2
SCHEMBL1060457 0.81 CACNA1I (0.82) CACNA1ICACNA1GCACNA1HCNR2KCNH2
SCHEMBL3105419 0.81 CACNA1I (0.64) CACNA1ICACNA1GCACNA1HCNR2KCNH2
SCHEMBL3099386 0.81 CACNA1I (0.66) CACNA1ICACNA1GCACNA1HCNR2KCNH2
SCHEMBL3090917 0.81 CACNA1I (0.64) CACNA1ICACNA1GCACNA1HCNR2KCNH2
SCHEMBL3102313 0.81 CACNA1I (0.64) CACNA1ICACNA1GCACNA1HCNR2KCNH2
SCHEMBL3058946 0.81 CACNA1I (0.63) CACNA1ICACNA1GCACNA1HCNR2KCNH2
SCHEMBL3085485 0.81 CACNA1H (0.66) CACNA1ICACNA1GCACNA1HCNR2KCNH2
SCHEMBL1062188 0.80 CACNA1I (0.80) CACNA1ICACNA1GCACNA1HCNR2KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100249176-A1 HETEROCYCLE AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS BARROW JAMES C 2010-09-30 US claimed
US-20100249176-A1 HETEROCYCLE AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS BARROW JAMES C 2010-09-30 US disclosed
US-20100249176-A1 HETEROCYCLE AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS BARROW JAMES C 2010-09-30 US disclosed
US-20100249176-A1 HETEROCYCLE AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS BARROW JAMES C 2010-09-30 US disclosed
WO-2009054983-A1 HETEROCYCLE AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS MERCK & CO., INC. (US) 2009-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249176-A1 HETEROCYCLE AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS CACNA1G, CACNA1H, CACNA1I CACNA1I 3/4885CACNA1G 1/4885CACNA1H 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.